[go: up one dir, main page]

DK0532525T3 - Nye protein-polykationkonjugater - Google Patents

Nye protein-polykationkonjugater

Info

Publication number
DK0532525T3
DK0532525T3 DK91909227.0T DK91909227T DK0532525T3 DK 0532525 T3 DK0532525 T3 DK 0532525T3 DK 91909227 T DK91909227 T DK 91909227T DK 0532525 T3 DK0532525 T3 DK 0532525T3
Authority
DK
Denmark
Prior art keywords
protein
conjugates
complexes
novel protein
cells
Prior art date
Application number
DK91909227.0T
Other languages
English (en)
Inventor
Max L Birnstiel
Matthew Cotten
Ernst Wagner
Original Assignee
Genentech Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25594931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0532525(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4110410A external-priority patent/DE4110410C2/de
Application filed by Genentech Inc, Boehringer Ingelheim Int filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0532525T3 publication Critical patent/DK0532525T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Manufacturing & Machinery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
DK91909227.0T 1990-05-18 1991-05-10 Nye protein-polykationkonjugater DK0532525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT111090 1990-05-18
DE4110410A DE4110410C2 (de) 1991-03-29 1991-03-29 Neue Protein-Polykation-Konjugate

Publications (1)

Publication Number Publication Date
DK0532525T3 true DK0532525T3 (da) 1995-12-04

Family

ID=25594931

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91909227.0T DK0532525T3 (da) 1990-05-18 1991-05-10 Nye protein-polykationkonjugater

Country Status (9)

Country Link
US (1) US20020044937A1 (da)
EP (1) EP0532525B1 (da)
JP (1) JP3222461B2 (da)
AT (1) ATE126442T1 (da)
DE (1) DE59106279D1 (da)
DK (1) DK0532525T3 (da)
ES (1) ES2078521T3 (da)
GR (1) GR3018029T3 (da)
WO (1) WO1991017773A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
DE4104186A1 (de) * 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
DE4110409C2 (de) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
DE4115038A1 (de) * 1991-05-08 1992-11-12 Genentech Inc Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1993019768A1 (en) * 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
FR2715847B1 (fr) * 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US6468981B1 (en) 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
JPH0889278A (ja) * 1994-09-29 1996-04-09 Ajinomoto Co Inc 遺伝子導入用修飾蛋白質及びその製法
GB9422495D0 (en) * 1994-11-08 1995-01-04 Medical Res Council DNA transfer method
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
US6153596A (en) * 1996-12-18 2000-11-28 Emory University Polycationic oligomers
EP0946878A1 (en) * 1996-12-23 1999-10-06 Cobra Therapeutics Limited Optimization of gene delivery and gene delivery systems
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
EP0969873B1 (en) * 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
JP4220673B2 (ja) 1998-07-21 2009-02-04 ミリポア・コーポレイション 遍在性クロマチンオープニングエレメント（ｕｃｏｅ）を含むポリヌクレオチド
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
CN1418224A (zh) 2000-03-02 2003-05-14 Ml实验室公开有限公司 Tcf效应元件
AU2001260729A1 (en) * 2000-07-26 2002-02-13 Cho, Sung-Woo Oligolysine transducing domain, oligolysine-cargo molecule complex and uses thereof
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) * 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates

Also Published As

Publication number Publication date
JPH05506991A (ja) 1993-10-14
WO1991017773A3 (de) 1991-12-26
ATE126442T1 (de) 1995-09-15
JP3222461B2 (ja) 2001-10-29
GR3018029T3 (en) 1996-02-29
ES2078521T3 (es) 1995-12-16
DE59106279D1 (de) 1995-09-21
WO1991017773A2 (de) 1991-11-28
EP0532525A1 (de) 1993-03-24
US20020044937A1 (en) 2002-04-18
EP0532525B1 (de) 1995-08-16

Similar Documents

Publication Publication Date Title
DK0532525T3 (da) Nye protein-polykationkonjugater
SE8800731L (sv) Fenylkarbamat
NL930119I1 (nl) Farmaceutische en veterinaire preparaten van cysteine-125-verminderde muteïnen van interleukine-2 ende produktie daarvan
DE3676670D1 (de) Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
OA04785A (fr) Esters d'amino acides.
SE427460B (sv) Pyrimidin(5)yl(tiono)(tiol)-fosfor(fosfon)-syraestrar och -esteramider till anvendning som insekticider, akaricider och nematocider
AU472833B2 (en) N-sulphenylated n-methylcarbamic acid aryl esters and their use as insecticides, acaricides and nematicides
DK0577648T3 (da) Nye protein-polykation-konjugater
DE3875396D1 (de) Mikrotraegermaterial fuer die zellkultur.
IT8721538A0 (it) Tiometil e sulfinil metil derivati ad azione antisecretiva acida gastrica, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
SE409208B (sv) Pyrimidin (4)-yl-(tiono)-(tiol)-fosfor(fosfon)syraestrar resp -esteramider till anvendning som insekticider och akaricider
IT7922818A0 (it) Procedimento per mantenere attiva la cultura di fermenti.
GB1380898A (en) Bonding of enzymes enzyme derivatives and other biologically active compounds to polymeric materials and polymeric materials to which such biologically active compounds can be bound
DE3786199D1 (de) Artikel fuer die verabreichung pharmakologisch aktiver substanzen.
IT7822316A0 (it) Composizione farmaceutica per la somministrazione di pancreatina.
IT991178B (it) Procedimento per migliorare le proprieta di bagnabilita di super fici di materia artificiale utili come supporto per la coltura di cellule di tessuti
AU6511074A (en) PHARMACOLOGICALLY ACTIVE 4, 8-DIMETHOXY-FURO-(3',2'-F) BENZOXAZOL-2-yl ACETHYDROXAMIC ACID
BE799299A (fr) Nouveaux esters et esteramides d'acides 3,4-dihydro-4-oxo-quinazolino (thiono)-phosphoriques (phosphoniques) leur procede de preparation et leur application comme insecticides et acaricides
BE818006A (fr) Depyrogenation de l'urokinase.
SU640003A1 (ru) Стыковое соединение
FR2358403A1 (fr) Nouveaux 2-imino-1,3-benzodithiolannes utiles notamment comme anti-inflammatoires
SU596559A1 (ru) Шихта дл изготовлени керамических изделий
GR3002665T3 (en) Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host
SE7902393L (sv) Biologiskt aktiva, nya 8 beta-hydrazinometyl-erolinderivat jemte sett for deras framstellning
JPS51138650A (en) Process for preparing optically active trans-cyclopentene-3,5,-diolmon oester

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment